Article
Capital Markets – Revival Or Reconfiguration?
The life sciences capital markets are showing signs of recovery in 2026, but the path to funding has fundamentally shifted. While biotech IPOs have exceeded 2025 totals in just the first quarter, a deeper analysis reveals that licensing deals now dwarf traditional public offerings, raising questions about whether we're witnessing a market rebound or an entirely new corporate development paradigm.
Ballard Spahr LLP